Data processing: measuring – calibrating – or testing – Measurement system in a specific environment – Biological or biochemical
Reexamination Certificate
2009-03-06
2011-10-04
Borin, Michael (Department: 1631)
Data processing: measuring, calibrating, or testing
Measurement system in a specific environment
Biological or biochemical
C703S011000
Reexamination Certificate
active
08032308
ABSTRACT:
Modeling of prognosis of survivability, side-effect, or both is provided. For example, RILI is predicted using bullae information. The amount, volume or ratio of Bullae, even alone, may indicate the likelihood of complication, such as the likelihood of significant (e.g., stage 3) pneumonitis. As another example, RILI is predicted using uptake values of an imaging agent. Standardized uptake from a functional image (e.g., FDG uptake from a positron emission image), alone or in combination with other features, may indicate the likelihood of side-effect. In another example, survivability, such as two-year survivability, is predicted using blood biomarkers. The characteristics of a patient's blood may be measured and, alone or in combination with other features, may indicate the likelihood of survival. The modeling may be for survivability, side-effect, or both and may use one or more of the blood biomarker, uptake value, and bullae features.
REFERENCES:
patent: 7844560 (2010-11-01), Krishnan et al.
patent: 2003/0017481 (2003-01-01), Golub et al.
patent: 2003/0120458 (2003-06-01), Rao et al.
Mahler et al. Air-fluid levels within lung bullae associated with pneumonitis Lung, vol. 159, No. 1, 163-171, 1981.
Aronberg et al. Lung carcinoma associated with bullous lung disease in young men. American Journal of Roentgenology, vol. 134, Issue 2, 249-252.
Logan, M. AJR:171, 569-577,1998.
Stanley et al. JNC3, vol. 63, No. 1, 25-32, 1980.
Ball et al, “Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy”, Int J Radiat Oncol Biol Phys 54:1007-13, 2002.
Bradley et al, “Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma”, Int J Radiat Oncol Biol Phys 52:49-57, 2002.
Dehing-Oberije et al, “Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy”, Int J Radiat Oncol Biol Phys 70:1039-44, 2008.
Brundage et al., “Prognostic factors in non-small cell lung cancer: a decade of progress”, Chest 122:1037-57, 2002.
Pfister et al., “American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003”, J Clin Oncol 22:330-53, 2004.
Firat et al., “Performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies”, Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 54:357-64, 2002.
“Chemotherapy for non-small cell lung cancer”, Non-small Cell Lung Cancer Collaborative Group. Cochrane Database Syst Rev:CD002139, 2000.
Basaki et al, “Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume”, Int J Radiat Oncol Biol Phys 64:449-54, 2006.
Werner-Wasik et al., “Increasing Tumor Volume is Predictive of Poor Overall and Progression-Free Survival: Secondary Analysis of the Radiation Therapy Oncology Group 93-11 Phase I-II Radiation Dose-Escalation Study in Patients with Inoperable Non-Small-Cell Lung Cancer”, Int J Radiat Oncol Biol Phys 70:385-90, 2008.
Zhao et al, “High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer”, Int J Radiat Oncol Biol Phys 68:103-10, 2007.
Solan et al., “Prognostic factors in non-small cell lung cancer”. Semin Surg Oncol 21:64-73, 2003.
Wulfkuhle et al., “Genomic and proteomic technologies for individualisation and improvement of cancer treatment”, Eur J Cancer 40:2623-32, 2004.
Boldrini et al., “Pognostic significance of osteopontin expession in early-stage non-small-cell lung cancer”,Br J Cancer 93:453-7, 2005.
Donati et al, “Osteopontin expression and prognostic significance in non-small cell lung cancer”, Clin Cancer Res 11:6459-65, 2005.
Kaminska et al., “Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF—an independent prognostic factor”, Oncology 70:115-25, 2006.
Koukouraksi et al., “Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis”, Br J Cancer 89:877-85, 2003.
Le et al, “An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers”,Clin Cancer Res 12:1507-14, 2006.
Orditura et al., “Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis”, J Interferon Cytokine Res 22:1129-35, 2002.
Songur et al., “Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer”, Tumori 90:196-200, 2004.
Muley et al., “CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients”, Anticancer Res 24:1953-6, 2004MU.
Pujol et al, “CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients”, Br J Cancer 90:2097-105, 2004.
Swinson et al, “Cabon anhydrase IX expression , a novel surrogate marker of tumor hypoxia, is assoicated with a poor prognosis in non-small-cell lung cancer”, J Clin Oncol 21:473-82, 2003.
Sin et al.,“Systemic inflammation and mortality in chronic obstructive pulmonary disease”, Can J Physicol , Pharmacol 85:141-7, 2007.
Cox et al, “Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases” from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 27:493-8, 1993.
Burges, “A Tutorial on Support Vector Machines for Pattern Recognition”, Kluwer Academic Publishers, Boston, MA pp. 1-43; Appeared in: Data Mining and Knowledge Discovery 2, 121-167, 1998.
Verduijn, et al., “Prognostic Bayesian Networks I: Rationale, Learning Procedure, and Clinical Use”, Journal of Biomedical Informatics, 40(2007), pp. 607-618.
Peek, et al., “ProCarSur: A System for Dynamic Prognostic Reasoning in Cardiac Surge”, AIME 2007, LNAI 4594, pp. 336-340, 2007.
Farhangfar, et al, “Impact of Imputation of Missing Values on Classification Error for Discrete Data”, Pattern Recognition 41(2008) pp. 3692-3705.
Murphy, K., “Bayes Net Toolbox for Matlab”, Oct 19, 2007, URL: http://www. cs. ubc. ca/murphyk/Software/BNT/bnt.
Murphy, K., “The Bayes Net Toolbox for Matlab”, Computing Science and Statistics, vol. 33, No. 2 (Oct. 9, 2001), pp. 1024-1034.
Chickering, et al, “Large-Sample Learning of Bayesian Networks is NP-Hard”, Journal of Machine Learning Research 5 (2004) pp. 1287-1330.
Dehing-Oberue, et al, “Development and External Validation of Prognostic Model for 2-Year Survival of Non-Small-Cell Lung Cancer Patients Treated with Chemoradiotherapy”, Int. J. Radiation Oncology Biol. Phys., vol. 74, No. 2, pp. 355-362, 2009.
Eaton, et al, “Bayesian Structure Learning Using Dynamic Programming and MCMC”, 2007 Proceedings of the 23rd Annual Conference on Uncertainty in Artificial Intelligence (UAI-07).
Lam, et al, “Learning Bayesian Belief Networks An Approach Based on the MDL Principle”, 2nd Pacific Rim International Conference on Artificial Intelligence, 1992, pp. 1237-1243.
Fung, et al, “Finite Newton Method for Lagrangian Support Vector Machine C
de Ruysscher Dirk
Dehing-Oberije Cary
Fung Glenn
Krishnan Sriram
Lambin Philippe
Borin Michael
Ryan Joshua B.
Siemens Medical Solutions USA , Inc.
LandOfFree
Modeling lung cancer survival probability after or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modeling lung cancer survival probability after or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modeling lung cancer survival probability after or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4278345